LFMD Form 4: Shayna Webb Dray Performance Stock Vesting Increases Stake

Rhea-AI Filing Summary

Insider Form 4 summary: Shayna Webb Dray, listed as Chief Operating Officer and a director-level reporting person at LifeMD, Inc., reported an acquisition on 08/22/2025 of 30,000 shares of the issuer's common stock through the vesting of performance stock. The transaction price is reported as $0, and following the vesting Dray beneficially owns 295,000 shares. The Form 4 was signed on 08/26/2025. The filing indicates the shares were granted as performance stock that vested on the transaction date.

Positive

• Performance award vested, aligning the Chief Operating Officer's compensation with company performance
• Beneficial ownership increased to 295,000 shares, showing continued insider stake in the company

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: A senior officer received vested performance shares, moderately increasing insider ownership.

The grant vested into 30,000 common shares on 08/22/2025 at a reported price of $0, indicating these were performance-based equity awards, not open-market purchases. Post-transaction beneficial ownership is 295,000 shares, which reflects the officer's existing equity stake plus the newly vested awards. This filing is a routine disclosure of compensation-related equity vesting and does not on its face signal a change in corporate control or a market transaction.

Securities Analyst

TL;DR: The Form 4 documents non-cash vesting of performance stock by an insider, a standard compensation event.

The 30,000-share increase arises from performance stock vesting, reported with a $0 price, which is typical when awards convert to shares rather than reflecting a cash purchase. The overall beneficial holding of 295,000 shares is material to understanding insider alignment but the filing contains no transaction indicating sale or market activity. For investors, the record clarifies insider remuneration but provides no direct signal about trading intent or liquidity events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dray Shayna Webb

(Last) (First) (Middle)

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		A		30,000	A	$0(1)	295,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of performance stock which vested on August 22, 2025

	/s/ Shayna Webb Dray	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Shayna Webb Dray report on the Form 4 for LifeMD (LFMD)?

She reported the vesting and acquisition of 30,000 common shares on 08/22/2025, with a reported price of $0, resulting in 295,000 shares beneficially owned.

Was the transaction a market purchase or a grant vesting for LFMD?

The filing lists the transaction code as A and explains it represents a performance stock grant that vested, not an open-market purchase.

What is the reporting person's role at LifeMD in this Form 4?

The reporting person is listed as Chief Operating Officer and is indicated as a reporting insider on the Form 4.

When was the Form 4 signed and filed?

The document shows the reporting person signature dated 08/26/2025 following the 08/22/2025 vesting date.

Does the Form 4 show any sales or dispositions by the insider?

No. The filing reports only an acquisition of 30,000 shares via vesting and shows no disposals.